FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES
批准号:
6393608
负责人:
P Jeffrey Conn
金额:
$34.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-08-01 至 2004-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The hippocampus plays an important role in a number of normal physiological processes and in a variety of pathological conditions, including Alzheimer's disease and temporal lobe epilepsy. Development of a complete understanding of the molecular and cellular mechanisms involved in regulation of hippocampal function could lead to new strategies for treatment of these disorders. Until recently, it was thought that all of the actions of glutamate, the major excitatory neurotransmitter in the hippocampus, were mediated by activation of ligand-gated cation channels. However, it is now clear that glutamate also activates metabotropic glutamate receptors (mGluRs), that are coupled to effector systems through GTP binding proteins. mGluRs play a number of important roles in regulating cell excitability and synaptic transmission in the hippocampus. A complete understanding of both normal and pathological hippocampal function will require a detailed understanding of the roles of mGluRs in modulating hippocampal physiology and the molecular mechanisms involved in regulating signaling by members of this important receptor family. Eight m(GluR subtypes (mGluR1 - mGluR8) have been identified by molecular cloning. In the hippocampus, evidence suggests that m(GluR2, mGluR7 and mGluR8 are all localized on presynaptic glutamatergic nerve terminals where they may serve to inhibit glutamate release. However, the postulated roles of mGluR7 and mGluR8 in regulating transmission at specific hippocampal synapses have not been definitively established. We recently reported that mGluR- mediated regulation of glutamate release can be inhibited by activation of protein kinase C (PKC). However, at present, the mechanism by which PKC inhibits signaling by presynaptic mGluRs is not known. A series of studies is proposed in which a combination of anatomical, pharmacological, and genetic approaches will be used to rigorously test the hypothesis that mGluR7 and m(GluR8 serve as presynaptic receptors at two major hippocampal synapses. We will then employ biochemical, electrophysiological, and molecular approaches to rigorously test the hypothesis that activation of PKC inhibits the function of presynaptic mGluRs by directly phosphorylating the receptors and inhibiting receptor coupling to GTP binding proteins. These studies could lead to a fundamental advance in our understanding of the mechanisms involved in regulation hippocampal function and could have important implications regarding novel approaches to treatment of disorders involving pathological changes in the hippocampus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of mGlu receptor PAMs for treatment of schizophrenia
-
批准号:10531546
-
项目类别:
-
资助金额:$67.81万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
-
批准号:10305625
-
项目类别:
-
资助金额:$70.71万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
-
批准号:10450295
-
项目类别:
-
资助金额:$19.12万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Discovery of mGlu receptor PAMs for treatment of schizophrenia
-
批准号:10063834
-
项目类别:
-
资助金额:$71.46万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics
-
批准号:10477066
-
项目类别:
-
资助金额:$19.12万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics
-
批准号:10581793
-
项目类别:
-
资助金额:$7.66万
-
财政年份:2019
-
负责人:P Jeffrey Conn
-
依托单位:
Development of an M1 PAM experimental therapeutic for schizophrenia
-
批准号:9140071
-
项目类别:
-
资助金额:$182.77万
-
财政年份:2015
-
负责人:P Jeffrey Conn
-
依托单位:
Development of mGIuR5 NAMS for Treatment of Major Depression
-
批准号:8434427
-
项目类别:
-
资助金额:$134.01万
-
财政年份:2013
-
负责人:P Jeffrey Conn
-
依托单位:
Development of mGIuR5 NAMS for Treatment of Major Depression
-
批准号:8603872
-
项目类别:
-
资助金额:$120.61万
-
财政年份:2013
-
负责人:P Jeffrey Conn
-
依托单位:
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3
-
批准号:8726488
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2012
-
负责人:P Jeffrey Conn
-
依托单位:
Postdoctoral Training in CNS Drug Discovery Research
-
批准号:8479436
-
项目类别:
-
资助金额:$23.49万
-
财政年份:2011
-
负责人:P Jeffrey Conn
-
依托单位:
Postdoctoral Training in CNS Drug Discovery Research
-
批准号:8296276
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2011
-
负责人:P Jeffrey Conn
-
依托单位:
Postdoctoral Training in CNS Drug Discovery Research
-
批准号:8661292
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2011
-
负责人:P Jeffrey Conn
-
依托单位:
Postdoctoral Training in CNS Drug Discovery Research
-
批准号:8078638
-
项目类别:
-
资助金额:$11.78万
-
财政年份:2011
-
负责人:P Jeffrey Conn
-
依托单位:
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia
-
批准号:8605222
-
项目类别:
-
资助金额:$188.05万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia
-
批准号:8423776
-
项目类别:
-
资助金额:$180.53万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia
-
批准号:7778028
-
项目类别:
-
资助金额:$189.15万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia
-
批准号:8029598
-
项目类别:
-
资助金额:$187.45万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia
-
批准号:8231498
-
项目类别:
-
资助金额:$188.05万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
Administrative Core
-
批准号:7988515
-
项目类别:
-
资助金额:$15.93万
-
财政年份:2010
-
负责人:P Jeffrey Conn
-
依托单位:
海外基金